Peginterferon lambda-1a
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Peginterferon lambda-1a
- Accession Number
- DB14767
- Description
Peginterferon lambda-1a is under investigation in clinical trial NCT01754974 (Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Peginterferon lambda-1a
- External IDs
- BMS-914143
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- 0T0250N43U
- CAS number
- 914617-98-4
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Chronic Hepatitis C Virus (HCV) Infection 1 3 Completed Treatment Hepatitis C Viral Infection 1 3 Completed Treatment Hepatitis C Virus (HCV) Infection 4 3 Withdrawn Treatment Hepatitis C Virus (HCV) Infection 1 2 Active Not Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 2 Completed Treatment Hepatitis B Virus (HBV) 1 2 Completed Treatment Hepatitis C Viral Infection 2 2 Completed Treatment Hepatitis D, Chronic 1 2 Enrolling by Invitation Treatment Coronavirus Disease 2019 (COVID‑19) / COVID / COVID - 19 1 2 Not Yet Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on May 20, 2019 08:26 / Updated on June 12, 2020 10:53